Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension: A Double-Blind, Placebo-Controlled Study.
Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown. To evaluate the effect of oral treprostinil compared to placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy. In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for >30 days prior to randomization and had a 6-minute walk distance ≥150 m. The primary end point was the time to first adjudicated clinical worsening event: death, hospitalization due to worsening PAH, initiation of inhaled or parenteral prostacyclin therapy, disease progression, or unsatisfactory long-term clinical response. Clinical worsening occurred in 26% of the oral treprostinil group compared with 36% of placebo participants (hazard ratio 0.74; 95% confidence interval [CI], 0.56 to 0.97; P=0.028). Key measures of disease status, including functional class, Borg dyspnea score, and N-terminal-pro-brain natriuretic peptide, all favored oral treprostinil treatment at week 24 and beyond. A non-invasive risk stratification analysis demonstrated that oral treprostinil-assigned participants had a substantially higher mortality risk at baseline but achieved a lower risk profile from study weeks 12 through 60. The most common adverse events in the oral treprostinil group were headache, diarrhea, flushing, nausea, and vomiting. In participants with PAH, addition of oral treprostinil to approved oral monotherapy reduced the risk of clinical worsening. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). Clinical trial registration available at www.clinicaltrials.gov, ID NCT01560624.